Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Influenza vaccination induced leukocytoclastic vasculitis and pauci-immune crescentic glomerulonephritis

Autor: J Gree, N Yanai-Berar, F Nakhoul, O Ben-Itzhak

Publikováno v: Clinical nephrology. 58(3)

Influenza vaccination is a widely accepted practice, particularly among the elderly and high-risk individuals. Minor and transitory side effects following the vaccination are common, while systemic complications are infrequently reported. We describe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80b855415900ca5d6c6ec02698d89407
https://pubmed.ncbi.nlm.nih.gov/12356192

Minimal change glomerulonephritis associated with hydatid disease

Autor: R, Gelman, G, Brook, J, Green, O, Ben-Itzhak, F, Nakhoul

Publikováno v: Clinical nephrology. 53(2)

A 63-year-old man presented to our department with dyspnea and peripheral edema. A cystic mass in the right upper abdomen, consistent with echinococcal disease was discovered. Proteinuria was also present, and a nephrotic syndrome was diagnosed. The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::17a219757b8c8154313475cb8bcfb6fc
https://pubmed.ncbi.nlm.nih.gov/10711418

Case report: late aggressive meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia

Autor: M E, Stein, K, Drumea, J N, Guilbord, O, Ben-Itzhak, A, Kuten

Publikováno v: The British journal of radiology. 68(814)

The clinical, radiological and pathological findings in a 28-year-old female patient who developed aggressive meningioma 20 years after prophylatic cranial irradiation (PCI) for acute lymphoblastic leukaemia (ALL) are described here. Only four cases

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bd0fa136dc49027e99e60352d9ae214e
https://pubmed.ncbi.nlm.nih.gov/8705190

Phase II Study of Amrubicin in Patients with Refractory or Resistant Relapsed Small-Cell Lung Cancer: Japan Clinical Oncology Group Study (JCOG0901)

Autor: Masaharu Nishimura, G. Galffy, Q. Cheng, N. Stjepanovic, B. B. Oven Ustaalioglu, M.A. Damiano, G. Sajjady, J. Cai, B. Wallin, J. Dimitroulis, M. Reck, Judit Kocsis, B. Dome, S. Mellor, Y. Okuma, G. Le Teuff, N. Muzzafar, S. Yang, T. Tamura, S.A. Kazmi, G. Fust, H. Isobe, L. Graf, R. Eckert, D. Easty, S. Ahn, M. Chacon, D.A. Fennell, H. Daga, D. Pérez-Callejo, Raffaele Califano, Y. Ohe, Angela C. Casbard, Pablo Martinez, Y. Hosomi, H. Murakami, M. Salcedo, Y-C. Kim, Mustafa Canhoroz, Y. Fujita, A. Verlicchi, I. Oh, M.A. Burgio, S. Imtiaz, C. Kurkjian, M.A. Montero, A. Rosales, D. Pérez Callejo, C. Park, P. Ibeas, Susana Cedres, S. Heavey, Thierry Jahan, X. Wang, K. Kim, G. Stathopoulos, W. Sterlacci, M. Palka, N.B. Leighl, Satoshi Oizumi, Benjamin Besse, E. Almagro Casado, G. Gavelli, M. Yomoda, K. Takamura, C. Maximiano, J.W. Heyburn, Selcuk Seber, C. Lou, Wolfgang Hilbe, L. Tamasi, W. Mao, L. Ampollini, A. Santo, Jason F. Lester, D. Simos, H. Yang, J-C. Soria, H. Jamnig, S. Kuom, H. Ban, S. Sanna, Gareth Griffiths, Y. Ichinose, K. Na, D. Tsavdaridis, Taner Korkmaz, Z. Segota, R. Buosi, Lisette Sheena Nixon, G. Pall, K.A. Gately, M. Leschke, C. Martin, T. Schmid, P. Godwin, Hirotoshi Dosaka-Akita, M.E. Guiterrez, L. Lei, J. Edwards, C. Ho, Z. Prohaszka, David Planchard, H. Lu, Athanassios Argiris, J. Qin, M. Nevinny, Yvonne Summers, Y. Takagi, M. Endo, K.J. O'Byrne, T. Okamura, Z. Orosz, B. Cantos, A. Martinez, A. Falco, M. Mezzetti, E. Flechter, H. Watanabe, Umut Kefeli, G. Zangerl, M.S. Liew, R. Hassan, Serdar Turhal, A.C. Mita, I.A. Muazzam, Z. Bartfai, D. Nonaka, O.S. Breathnach, M. Monti, Harvey I. Pass, C. Poleri, O. Balvan, S. White, L. Mutti, J. Margery, W. Kim, Hedy L. Kindler, Hajime Asahina, M. Rosenberg, Mahmut Gumus, A. Pircher, A. López-González, N. Siddiqui, D. Torrejon Castro, V. Vilchez, R. Chacon, Dean A. Fennell, K. Umezawa, A. Szilagyi, T. Kojima, R. Mastico, Enriqueta Felip, Y. Zhang, P. Wheatley-Price, R. Guild, Rastilav Bahleda, D. Traphalis, M. Sergi, O. Ben Itzhak, T. Shibata, A.K. Patané, K. Das, S. Kumar, O. Vaisman, J. Stathopoulos, N. Yasar, W.M. Grogan, A. Soltermann, Steven G. Gray, H. Kang, J. Clince, M. Faehling, C.L. Hann, M. Barr, Lyudmila Bazhenova, B.G. Doger de Speville, A. Ruiz-Valdepeñas, Anne-Marie Baird, C. Kosmas, Y. Nakahara, T. Harada, J.D. Maltzman, M. Provencio Pulla, J. Parno, N. Yamamoto, M. Wollner, Antoine Hollebecque, David R. Spigel, Willi Oberaigner, Y. Kawai, M. Shibuya, E. Sari, E. Almagro-Casado, M. Mendez Garcia, N.J. Coleman, J. Raphael, Johanna C. Bendell, M. Fiegl, I. Opitz, G. Diaz, E. Jennions, Christophe Massard, G. Genestreti, M. Iguchi, P. Fatato

Publikováno v: Annals of Oncology. 23:ix492

Background Standard therapy for refractory or resistant relapsed small-cell lung cancer (SCLC) has not yet been established. We conducted an open-label, multicenter, non-randomized phase II study to confirm the efficacy and safety of amrubicin, a top

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3285e282bfecba0a422afa8f2b2c30d7
https://doi.org/10.1093/annonc/mds415